Azienda Ospedaliera Sant'Andrea-Università di Roma La Sapienza

Roma 00189

3 studies enrolling now · 15 studies all time

What they study most

Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chronic Kidney Disease, Diabetes Mellitus, Type 2, Endogenous Cushing's Syndrome, Heart Failure, Idiopathic Pulmonary Fibrosis, Kidney Disease, Chronic, Refractory Generalized Myasthenia Gravis, Relapsing-Remitting Multiple Sclerosis, Secondary Prevention

Studies at this site

• EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) — Recruiting now
• A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart — Recruiting now
• A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure — Recruiting now
• A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) — Completed
• Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) — Completed
• Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome — Running, not enrolling
• EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin) — Completed
• The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread — Completed
• EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved) — Completed
• EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced) — Completed
• Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200) — Completed
• CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes — Completed
• Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS) — Completed
• Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study) — Completed
• BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation — Completed